| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 6580- | EU, | Eurycomanone Blocks TGF-β1-Induced Epithelial-to-Mesenchymal Transition, Migration, and Invasion Pathways in Human Non-Small Cell Lung Cancer Cells by Targeting Smad and Non-Smad Signaling |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-1 |
| 6583- | EU, | Inactivation of AKT/NF-κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | Calu-1 |
| 6585- | EU, | Anti-Tumor Activity of Eurycoma longifolia Root Extracts against K-562 Cell Line: In Vitro and In Vivo Study |
| - | vitro+vivo, | AML, | K562 |
| 6390- | Eug, | Molecular mechanisms of eugenol as an antitumour bioactive compound: A comprehensive review |
| - | Review, | Var, | NA |
| 6391- | Eug, | BCP, | 5-FU, | Exploring Mechanism of Actions for Eugenol and Beta-Caryophyllene to Combat Colorectal Cancer Chemotherapy Using Network Pharmacology |
| - | in-vitro, | CRC, | HCT116 |
| 6381- | Eug, | Biological Properties and Prospects for the Application of Eugenol—A Review |
| - | Review, | Var, | NA |
| 6389- | Eug, | Molecular Insights into the Management of Eugenol's Anticancer Action Against Colon Cancer: A Detailed Review |
| - | Review, | Colon, | NA |
| 6388- | Eug, | Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review |
| - | Review, | Var, | NA |
| 6337- | Eug, | Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest |
| - | in-vitro, | BC, | MCF-10AT |
| 6338- | Eug, | Tumor suppressive roles of eugenol in human lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 6325- | Eug, | Anticancer Properties of Eugenol: A Review |
| - | Review, | Var, | NA |
| 6323- | Eug, | Eugenol: An Insight Into the Anticancer Perspective and Pharmacological Aspects |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA |
| 6331- | Eug, | Eugenol-Induced Autophagy and Apoptosis in Breast Cancer Cells via PI3K/AKT/FOXO3a Pathway Inhibition |
| - | in-vitro, | BC, | MDA-MB-231 |
| 6843- | EVO, | Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells |
| - | in-vivo, | PC, | PANC1 | - | in-vitro, | PC, | SW1990 |
| 6842- | EVO, | Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | LN229 |
| 6848- | EVO, | Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa |
| - | Review, | Nor, | NA |
| 3712- | FA, | Ferulic Acid: A Hope for Alzheimer’s Disease Therapy from Plants |
| - | Review, | AD, | NA |
| 3782- | FA, | Ferulic acid ameliorates bisphenol A (BPA)-induced Alzheimer’s disease-like pathology through Akt-ERK crosstalk pathway in male rats |
| - | in-vivo, | AD, | NA |
| 6881- | FA, | Potential Therapeutic Efficacy of Ferulic Acid and Its Derivatives in the Management of Cancers: A Comprehensive Analysis With Mechanistic Insight |
| - | Review, | Var, | NA |
| 6885- | FA, | Mitigation of renal toxicity induced by paraquat using ferulic acid: Role of inflammatory pathways |
| - | in-vivo, | Nor, | NA |
| 1654- | FA, | Molecular mechanism of ferulic acid and its derivatives in tumor progression |
| - | Review, | Var, | NA |
| 1656- | FA, | Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling |
| - | Review, | Var, | NA |
| 2847- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | in-vitro, | CCA, | NA |
| 2849- | FIS, | Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells |
| - | in-vitro, | Melanoma, | U266 |
| 2857- | FIS, | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
| - | Review, | Var, | NA |
| - | in-vitro, | OS, | U2OS |
| 2845- | FIS, | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
| - | Review, | Var, | NA |
| 2824- | FIS, | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
| - | Review, | Var, | NA |
| 2825- | FIS, | Exploring the molecular targets of dietary flavonoid fisetin in cancer |
| - | Review, | Var, | NA |
| 2826- | FIS, | Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway |
| - | in-vitro, | BC, | MDA-MB-453 |
| 2828- | FIS, | Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review |
| - | Review, | Var, | NA |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2830- | FIS, | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2843- | FIS, | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
| - | Review, | Var, | NA |
| 2832- | FIS, | Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies |
| - | Review, | Var, | NA |
| 6897- | FIS, | Fisetin: A Dietary Antioxidant for Health Promotion |
| - | Review, | Nor, | NA |
| 6911- | FIS, | New Mitochondria-Targeted Fisetin Derivative Compromises Mitophagy and Limits Survival of Drug-Induced Senescent Breast Cancer Cells |
| - | vitro+vivo, | BC, | NA |
| 6914- | FIS, | Fisetin inhibits inflammation and induces autophagy by mediating PI3K/AKT/mTOR signaling in LPS-induced RAW264.7 cells |
| - | in-vitro, | Nor, | RAW264.7 |
| 6922- | FIS, | Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin |
| - | Review, | Var, | NA |
| 6901- | FIS, | Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC |
| - | in-vivo, | HNSCC, | CAL33 |
| 6899- | FIS, | Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 6898- | FIS, | Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 949- | FIS, | ATAGJ, | Cisplatin, | Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway |
| - | in-vivo, | BC, | Walker256 | - | in-vitro, | BC, | Walker256 |
| 2313- | Flav, | Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism |
| - | Review, | Var, | NA |
| 6980- | Form, | The potential role of formononetin in cancer treatment: An updated review |
| - | Review, | Var, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6984- | Form, | Formononetin suppresses colitis-associated colon cancer by targeting lipid synthesis and mTORC2/Akt signaling |
| - | in-vitro, | Colon, | HCT116 | - | Review, | IBD, | RAW264.7 |
| 6991- | Form, | Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 6964- | Form, | Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo |
| - | vitro+vivo, | BC, | MCF7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:4 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid